Thermo Scientific Medical Device portfolio provides an extensive range of chromatography and mass spectrometry instruments for laboratory development test optimization

Thermo Fisher Scientific announces the expansion of its portfolio of analytical instruments for clinical diagnostic laboratories with the addition of three systems now listed as Class I medical devices with the United States Food and Drug Administration (U.S. FDA). The portfolio now offers clinical diagnostic laboratories access to additional instruments that can be used to develop sensitive, robust and reliable laboratory developed tests (LDTs).

The Thermo Scientific Medical Device (MD) portfolio of liquid chromatography-mass spectrometry (LC-MS) systems are U.S. FDA Class I medical devices that now include the Thermo Scientific Vanquish MD High Performance Liquid Chromatography (HPLC) system, the Thermo Scientific TSQ Altis MD Series mass spectrometer and the Thermo Scientific Quantis MD Series mass spectrometer. The new systems join the existing Prelude MD HPLC and Prelude LX-4 MD HPLC systems to form a more complete MD portfolio of analytical solutions that can enable diagnostic laboratories to achieve sensitivity, safeguard robustness and improve reliability. In addition, the enhanced product portfolio is designed to increase throughput of clinical diagnostic assays for the detection of small to large molecules within complex biological matrices.

Thermo Fisher Scientific showcased the new instrument portfolio during the 11th Annual North American Conference of The Association for Mass Spectrometry: Applications to the Clinical Laboratory (MSACL US 2019), held March 31–April 4, at Booth #4–6 at the Renaissance Hotel and Convention Center, Palm Springs, California.

"Clinical laboratories are under pressure to develop and optimize sensitive and reliable laboratory developed tests that play an essential role in the diagnosis and monitoring of acute and chronic diseases," said Bradley Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific. "With the new MD portfolio of Class I medical devices with the U.S. FDA, scientists in clinical diagnostic laboratories can now choose from a unique portfolio of liquid chromatography and mass spectrometry platforms to develop and optimize assays essential for clinical decision-making."

Designed to bring high-quality analytical performance to clinical diagnostic laboratories, the TSQ Altis MD Series MS and TSQ Quantis MD series mass spectrometers enable high robustness and sensitivity for analysis and quantitation of complex biological samples. The Vanquish MD HPLC system offers separation capabilities that can enhance the resolution of analytes.

The MD portfolio is powered by Thermo Scientific TraceFinder LDT 1.0 Software, providing a regulatory compliance management software solution to enable management of clinical diagnostic workflows. In addition, Thermo Fisher Scientific has collaborated with BYG Informatique on a middleware solution that can enable seamless integration of data from TraceFinder LDT 1.0 to most laboratory information management systems (LIMS) used by diagnostic laboratories.

more on the MD portfolio

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.

more news from this company